 RedHill Biopharma Ltd. NASDAQ:RDHL said it has completed enrollment and randomized the last patient in the global Phase 23 study with oral opaganib in patients hospitalized with severe coronavirus COVID-19 pneumonia positioning it as a frontrunner in the hunt for an oral pill to treat COVID-19. 